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Abstract
Background: Thyroid hormone treatment in children with congenital hypothyroidism can prevent intellectual
disability. Guidelines recommend that children diagnosed with congenital hypothyroidism through newborn
screening remain on treatment to at least 3 years of age, after which a trial off therapy can determine which
children have transient hypothyroidism. The purpose of this study was to describe the rate at which children with
congenital hypothyroidism in the United States discontinue thyroid hormone treatment in early childhood.
Methods: Retrospective analysis of the 2002-2006 MarketScan® Commercial Claims and Encounters research
databases and the 2001-2005 MarketScan Multi-State Medicaid databases. Children were classified as having
congenital hypothyroidism based on billing codes and having filled a prescription for thyroid hormone treatment.
Kaplan-Meier curve analysis was used to determine discontinuation rates.
Results: There were a total of 412 Medicaid-enrolled children and 292 privately-insured children with presumed
congenital hypothyroidism included in this study. The overall birth prevalence of congenital hypothyroidism across
both datasets was about 1 per 2,300. By 36 months, the percentage who had discontinued thyroid replacement
treatment was 38% (95% Confidence Interval: 32%-44%). Medicaid-enrolled children had a more rapid decline in
the first 24 months of treatment compared to those with private insurance (P = 0.02).
Conclusions: More than one-third of children treated for congenital hypothyroidism discontinued treatment within
36 months, which is inconsistent with current guidelines. It is not known how many of these children required
continued treatment or experience adverse effects from discontinuation. These findings emphasize the critical need
for follow-up systems to monitor the outcome of newborn screening.
Background
Although there has been dramatic expansion in the con-
ditions identified by newborn screening, few data are
available regarding the care that children receive after
they are diagnosed through newborn screening. Appro-
priate delivery of health care services is necessary to
assure the benefit of early diagnosis. We chose to focus
on congenital hypothyroidism (CH) because of its rela-
tively high prevalence compared to other conditions
included in newborn screening and because treatment is
among the most straight-forward.
Newborn screening for CH followed by the early
initiation of thyroid hormone treatment to normalize
thyroxin (T4) concentrations has been shown to prevent
intellectual disability (i.e., mental retardation) [1-3].
Among population-based studies of children born prior
to the introduction of newborn screening for CH in the
late 1970s, 8% to 29% of children with clinically diag-
nosed CH received special education services for intel-
lectual disability [4-6].
Despite the unquestioned public health success from
newborn screening and the management of CH, there
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has been a sustained rise in the reported frequency of
CH among infants in the United States (US) from 24.4
per 100,000 in 1987 to 42.2 per 100,000 in 2002[7]. It is
unknown whether this reflects a real increase[8]. In
Australia, increased birth prevalence of CH has been
tied to changes in diagnostic criteria and clinical prac-
tice[9].
One important challenge in understanding the epide-
miology of CH is that some newborns will have transi-
ent CH, a temporary depression of thyroid hormone
concentrations that can last from several days to several
months[8]. If confirmatory testing during the first
month indicates CH, US guidelines call for children to
remain on treatment to at least 3 years of age, after
which a trial of withdrawal off treatment can determine
which children have transient hypothyroidism[10]. Stu-
dies from other countries have reported that 10 to 15%
of children treated for CH ultimately prove to not need
treatment past 3 years of age to maintain normal hor-
mone concentrations, and thus have transient hypothyr-
oidism[11,12]. This percentage could be higher in the
US, particularly if physicians are more likely to assign a
diagnosis and prescribe thyroid hormone therapy, which
is considered safe and inexpensive, while waiting for
more definitive test results. Little is known about how
many children in the US have either permanent or tran-
sient CH.
It is not known how many children treated for CH
discontinue treatment, with or without physician super-
vision. The purpose of this study was to explore the
birth prevalence of presumed CH, the relationship of
presumed CH to sex, and the rate at which children
diagnosed with CH in the US discontinue thyroid hor-
mone treatment in early childhood. Children who dis-
continued treatment may have had either transient CH
or a mild form of permanent CH.
Methods
The study design was a retrospective analysis of health
insurance claims databases in which infants treated for
CH were followed over time to determine when treat-
ment stopped based on the lack of thyroid hormone
treatment prescription refills. We used health insurance
claims data to conduct a retrospective cohort study of
infants with presumed CH to track use of thyroid hor-
mone treatment by individuals with continued enroll-
ment in the same health plan.
Data Sources
We analyzed two different sources of data, the Market-
Scan Commercial Claims and Encounters research data-
bases for the years 2002-2006 and the MarketScan
Multi-State Medicaid databases for the years 2001-2005
from Thomson Reuters. The MarketScan research data-
bases contain information on inpatient, outpatient, and
prescription drug claims for enrolled individuals which
allow for tracking of services received by the same indi-
viduals over time as long as they remain enrolled. Two
of us (S.D.G., L.O.) initially analyzed data on privately-
insured children from the Commercial database consist-
ing and presented preliminary findings at a Centers for
Disease Control and Prevention workshop in February
2008[13]. The present study replicated that analysis with
an analysis of the independently collected MarketScan
Multi-State Medicaid data.
The MarketScan Commercial databases contain infor-
mation from the private health insurance plans of about
100 self-insured employers each year, including large
private employers and state governments. We excluded
those plans that do not submit pharmacy claims. Drug
claims in the Commercial database include claims where
individual copays fully met the pharmacy cost with no
additional health plan reimbursement. The Multi-State
Medicaid databases contain claims data from eight uni-
dentified states and include drug claims data for all
enrollees. Unlike the Commercial database, few Medi-
caid drug claims were associated with copays.
Although drug claims are well-coded, specific labora-
tory tests (e.g., thyroid stimulating hormone [TSH], free
T4) or imaging studies (e.g., thyroid ultrasound, thyroid
nuclear medicine scans) do not always appear properly
coded within the databases. To protect subject confiden-
tiality, both the Multi-State Medicaid and Commercial
databases include only birth year but not exact birth
date. In our experience, race and ethnicity are not reli-
ably coded in these databases[14]. The only other demo-
graphic variable is sex.
Birth Prevalence of Presumed Congenital Hypothyroidism
We considered a child to have presumed CH if they had
at least one outpatient claim for CH (International Clas-
sification of Diseases, Ninth Revision [ICD-9] code 243)
and one or more filled prescriptions for thyroid hor-
mone therapy during their first year of life. The overall
birth prevalence was calculated separately for Medicaid-
enrolled children and privately insured children as the
percentage of newly diagnosed and treated cases of CH
among all children born during the study years. We cal-
culated the 95% confidence interval (CI) based on the
expected binomial distribution of this count data.
Rate of Thyroid Hormone Treatment Continuation
Kaplan-Meier analysis was used to evaluate the rate of
continuation of thyroid hormone treatment by number
of months since the initiation of treatment adjusted for
censoring due to individuals discontinuing health plan
enrollment or coverage. This was based on the total
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assessed by cumulative duration of prescription being
filled, by children who were born in 2001-2005 in the
Multi-State Medicaid databases or who were born in
2002-2006 in the Commercial databases. We were not
able to determine the ages in months over which treat-
ment was received because of the lack of exact birth
dates in the databases.
Throughout our analyses, we made a conservative
assumption that would bias towards longer rates of
treatment. The quantity of drug supplied is not recorded
in pharmacy claims. Because prescriptions can be filled
for up to 3 months and families may have some extra
supply at home due to skipped doses, children may con-
tinue on treatment for several months after the last
claim is filed. Therefore, we considered thyroid hormone
treatment to be discontinued if there were no prescrip-
tion claims by the fourth month after the last prescrip-
tion was filled. In the Kaplan-Meier analysis, individuals
were right censored if they were no longer in the claims
databases during the fourth month after the last pre-
scription refill or if the fourth month fell outside of the
study period. We constructed Kaplan-Meier survival
curves to estimate the probability of continued thyroid
hormone treatment at each month since initiation of
treatment stratified by insurance type (Medicaid vs. pri-
vate health insurance). To evaluate the replication of
our analyses in the two independent datasets, we used
the log-rank test for equality of Kaplan-Meier functions.
We similarly evaluated the relationship between sex
and discontinuation. We hypothesized that females were
more likely to continue thyroid hormone treatment
because the prevalence of permanent congenital
hypothyroidism is about twice as high among females
than males[12]. In contrast, transient or very mild per-
manent CH is equally common among females and
males[12].
Data Analysis
All analyses were conducted with Stata 10 statistical
software (College Station, TX). We considered P <0 . 0 5
to be statistically significant. This study was approved
b yt h eD u k eU n i v e r s i t yM e d i c a lC e n t e ri n s t i t u t i o n a l
review board. No other approval was required for the
use of the claims data.
Results
Prevalence of Presumed Congenital Hypothyroidism
There were a total of 412 Medicaid-enrolled children
born during the years 2001-2005 who met the case defi-
nition for presumed CH, yielding a birth prevalence of
47 per 100,000 (95% CI: 42 - 51 per 100,000). A total of
292 privately-insured children born during the years
2002-2006 met the case definition for presumed CH, for
a similar birth prevalence (44 per 100,000 [95% CI: 39-
49 per 100,000]). The birth prevalence was approxi-
mately 1 in 2,300 in both cohorts.
Rate of Thyroid Hormone Continuation
Among the Medicaid-enrolled children with presumed
CH, there were a total of 7,023 person-months of thyr-
oid hormone treatment compared to 5,202 person-
months of thyroid hormone treatment among those
with private health insurance. Figure 1 presents a
Kaplan-Meier curve for the continuation of thyroid hor-
mone treatment among the Medicaid-enrolled and pri-
vately insured cases of presumed CH. Table 1 presents
the cumulative rate of discontinuation in six-month
intervals through 42 months of treatment. Although
Medicaid-enrolled children had a more rapid initial
decline in the rate of continuation in the first 24 months
of treatment compared to those with private insurance
(P = 0.02), by 36 months the percentage who had dis-
continued thyroid hormone treatment was similar
between Medicaid-enrolled (40% [95% CI: 34%-48%])
and privately insured children (33% (95% CI: 24%-44%).
The overall percentage who had discontinued by 36
months was 38% (95% CI: 32% - 44%).
Relationship of Presumed CH to Sex
In the birth year, females represented 53% (n = 368) of
all cases (i.e., ratio of females to males of 1.1:1). Males
were more likely to discontinue thyroid hormone treat-
ment (P = 0.04) over time. Among those that continued
for more than 36 months, the ratio of females to males
was 1.8:1 (95% CI: 1.14:1 - 2.98:1).
Discussion
To our knowledge, this is the first study to examine
rates of discontinuation of thyroid hormone therapy
among a broad cross-section of US children diagnosed
with CH. In contrast, the Texas newborn screening fol-
low-up program found that very few children with CH
managed by pediatric endocrinologists are reclassified as
having transient CH[8]. The finding that approximately
40% of children with CH appear to discontinue treat-
ment by 36 months after initiation of treatment was
unexpected. We are reassured that these results are cor-
rect based on agreement with the accepted birth preva-
lence of CH and the concordance of our replicated
findings. We found a birth prevalence of presumed CH
of about 1 in 2,300 in both samples, consistent with the
prevalence of CH reported from U.S. newborn screening
records[7,15]. We also found similar rates of thyroid
hormone treatment discontinuation independently in
both samples. However, the patterns differed signifi-
cantly by duration of treatment, with higher period-spe-
cific discontinuation rates before 24 months in the
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tion rates in the Commercial sample after 24 months.
We do not know the underlying causes of this
difference.
According to current guidelines, children with con-
firmed CH should remain on treatment until at least 36
months of age. Only then should those who are not
known to have an absent or dysplastic thyroid gland
undergo carefully monitored trial withdrawal of therapy
[10]. We suspect that discontinuation of thyroid hor-
mone treatment within six months of its start represents
cases where presumptive treatment was begun based on
preliminary test results and then stopped after
confirmatory testing ruled out CH. The 5 to 15% dis-
continuation rate during the first 6 months is consistent
with that interpretation. However, between 6 and 36
months few children should undergo discontinuation if
parents and physicians follow the CH management
guidelines. Our findings of discontinuation during this
period appear inconsistent with the guidelines. It may
be that families are stopping treatment and that their
children do not receive monitoring to assure that thyr-
oid hormone concentrations are in the normal range.
This hypothesis is consistent with the preliminary find-
ings of a survey of families of 23 children with border-
line CH conducted by the Michigan Department of
Community Health newborn screening follow-up pro-
gram, seven of whom (30%) reported stopping treatment
on their own, without medical advice[16].
W ea r ec o n c e r n e dt h a ta ni m p o r t a n tn u m b e ro fc h i l -
dren for whom treatment was discontinued likely had
p e r m a n e n tC H ,a n dt h a tt h e s ec h i l d r e ns h o u l dh a v e
remained on treatment. If so, it is likely that such chil-
dren may have milder forms of CH, for which the
effects of thyroid hormone treatment discontinuation
may not be readily apparent.
As expected, we found that children treated for CH
who stopped treatment within roughly 3 years of begin-
ning treatment have a nearly balanced sex ratio. In con-
trast, those who continued treatment past 36 months
had a roughly two to one ratio of females to males, as is
Figure 1 Kaplan-Meier Curve for the Continuation of Thyroid Hormone Treatment for Children with Presumed Congenital
Hypothyroidism, by Insurance Type.
Table 1 Rates of Cumulative Thyroid Hormone
Discontinuation for Children with Presumed Congenital
Hypothyroidism by Insurance Type in Six-Month
Increments from Initiation of Therapy
Duration Medicaid
Rate (95% CI*)
Private Health Insurance
Rate (95% CI*)
6 Months 11% (9%-15%) 7% (5%-11%)
12 Months 19% (15%-24%) 11% (8%-16%)
18 Months 26% (21%-31%) 14% (10%-20%)
24 Months 34% (28%-40%) 15% (10%-21%)
30 Months 38% (32%-45%) 21% (15%-28%)
36 Months 40% (34%-48%) 33% (24%-44%)
42 Months 45% (37%-52%) 39% (29%-50%)
*CI: Confidence Interval
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[9,17-19] and those with thyroid dysgenesis in particular
[12,20]. These findings suggest that those who discon-
tinued early had false positive newborn screening results
or transient hypothyroidism, and that the bulk of those
who continued treatment had permanent CH. However,
these data do not provide insight into how many chil-
dren may have appropriately or inappropriately stopped
receiving thyroid hormone treatment.
Limitations
Our study had several limitations. One of these is com-
mon to both research databases. First, for most children
we were not able to ascertain which laboratory tests
were conducted and we had no information on the
results of laboratory tests. Two other limitations were
specific to the MarketScan Commercial database sample:
high rates of attrition due to disenrollment and the pos-
sibility that co-pays for prescriptions might have led to
prescriptions being filled elsewhere, perhaps reimbursed
by a different parent’s health plan. Neither of these lim-
itations applies to the MarketScan Multi-State Medicaid
database. The similarity in findings between the analyses
of data from two independent samples strengthens the
credibility of the findings.
Conclusions
Long-term follow-up of US children diagnosed with CH
and other disorders detected by newborn screening is
needed to assure the continued receipt of appropriate
treatment and the full realization of the health gains
from early detection of inborn errors. Although approxi-
mately 80% of cases of CH are sporadic rather than
genetic in origin,[21] close management and monitoring
of genetic disorders such as sickle cell disease is also
essential. Limited adherence to penicillin prophylaxis
among children with sickle cell disease is widely
reported [22-24]. As a result, the potential to prevent
invasive pneumococcal disease and associated mortality
through newborn screening was realized only in part.
The subsequent introduction in 2000 of the heptavalent
pneumococcal conjugate vaccine was associated with a
greater than 40% reduction in sickle cell disease-related
mortality among Black or African-American children
under 5 years of age[25].
It appears that many US children with CH may have
treatment discontinued inappropriately, although this does
not appear to be the case among children with CH mana-
ged by endocrinologists[8]. This could potentially cause
long-term harm for at least some children with permanent
CH. Unfortunately, newborn screening program records
a r ei n a d e q u a t ef o rt h es u r v e i l l a n c eo fC H ,b o t ht oa s s e s s
prevalence and time trends. Without additional data, we
cannot determine whether the reported increase in CH
prevalence in the US in recent decades [7] is real or arti-
factual, or the degree to which discontinuation of thyroid
hormone treatment may be appropriate. Public health
responsibility requires the collection of long-term follow-
up data [26] to address these fundamental questions. Such
data need to include findings from laboratory tests of thyr-
oid hormone status and be representative of all children
with CH, not just those managed by pediatric endocrinol-
ogists. Developing a system to evaluate health services
delivery and health outcomes for individuals diagnosed
with CH through newborn screening would be an impor-
tant model for monitoring the impact of newborn screen-
ing more broadly. In the meantime, practical interventions
are required to assure adherence to available guidelines.
To help with this, the US Health Resources and Services
Administration has developed a national network of regio-
nal coordinating centers to disseminate guidelines and
work with primary care providers, specialists, and families
to improve care delivery for children who had a positive
newborn screen[27].
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